What Is ARA-290?

Also known as: Cibinetide, Innate repair receptor agonist

ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B region of erythropoietin. It activates the 'innate repair receptor' (an EPO/β-common receptor complex) that drives tissue protection, without touching the classical EPO receptor that raises red blood cells.

That split let researchers pursue EPO's healing effects without its blood-thickening risk. Human trials in sarcoidosis-associated small fiber neuropathy showed reduced pain and regrowth of small nerve fibers in the skin at 4 mg daily for 28 days.

What is ARA-290 studied for?

Side effects & safety

Trials reported a safety profile similar to placebo; injection-site reactions are the main community complaint. No effect on hematocrit by design.

Legal & approval status

Investigational; not approved anywhere. Sold as a research peptide.

Typical dosing at a glance

Commonly reported protocols use 1 mg–4 mg, daily, typically 28-day course, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the ARA-290 reconstitution calculator →

Related peptides

What is BPC-157?What is Pentadeca Arginate (PDA)?What is TB-500?What is GHK-Cu?What is KPV?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.